MXPA99007999A - Pet food composition - Google Patents
Pet food compositionInfo
- Publication number
- MXPA99007999A MXPA99007999A MXPA/A/1999/007999A MX9907999A MXPA99007999A MX PA99007999 A MXPA99007999 A MX PA99007999A MX 9907999 A MX9907999 A MX 9907999A MX PA99007999 A MXPA99007999 A MX PA99007999A
- Authority
- MX
- Mexico
- Prior art keywords
- pet food
- food product
- clause
- composition
- fibers
- Prior art date
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 63
- 239000000203 mixture Substances 0.000 title claims description 69
- 239000000835 fiber Substances 0.000 claims abstract description 86
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract description 27
- 239000011574 phosphorus Substances 0.000 claims abstract description 27
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 26
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 23
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 23
- 239000005416 organic matter Substances 0.000 claims abstract description 21
- 230000008034 disappearance Effects 0.000 claims abstract description 13
- 241000894006 Bacteria Species 0.000 claims abstract description 11
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 11
- 230000000153 supplemental effect Effects 0.000 claims abstract description 9
- 235000005911 diet Nutrition 0.000 claims description 80
- 230000037213 diet Effects 0.000 claims description 80
- 235000016068 Berberis vulgaris Nutrition 0.000 claims description 32
- 241000335053 Beta vulgaris Species 0.000 claims description 32
- 235000018102 proteins Nutrition 0.000 claims description 22
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 16
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 16
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 14
- 241001541238 Vachellia tortilis subsp. raddiana Species 0.000 claims description 11
- 241000207199 Citrus Species 0.000 claims description 9
- 108010068370 Glutens Proteins 0.000 claims description 9
- 240000008042 Zea mays Species 0.000 claims description 9
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 9
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 9
- 235000020971 citrus fruits Nutrition 0.000 claims description 9
- 235000005822 corn Nutrition 0.000 claims description 9
- 235000021312 gluten Nutrition 0.000 claims description 9
- 235000012054 meals Nutrition 0.000 claims description 9
- 229940071440 soy protein isolate Drugs 0.000 claims description 9
- 235000019766 L-Lysine Nutrition 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 8
- 229960004799 tryptophan Drugs 0.000 claims description 8
- 244000215068 Acacia senegal Species 0.000 claims description 7
- 229920000084 Gum arabic Polymers 0.000 claims description 7
- 239000000205 acacia gum Substances 0.000 claims description 7
- 235000010489 acacia gum Nutrition 0.000 claims description 7
- 235000019750 Crude protein Nutrition 0.000 claims description 5
- 239000001814 pectin Substances 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 239000001508 potassium citrate Substances 0.000 claims description 4
- 229960002635 potassium citrate Drugs 0.000 claims description 4
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 4
- 235000011082 potassium citrates Nutrition 0.000 claims description 4
- 229920000161 Locust bean gum Polymers 0.000 claims description 3
- 240000007594 Oryza sativa Species 0.000 claims description 3
- 235000007164 Oryza sativa Nutrition 0.000 claims description 3
- 239000000711 locust bean gum Substances 0.000 claims description 3
- 235000010420 locust bean gum Nutrition 0.000 claims description 3
- 235000009566 rice Nutrition 0.000 claims description 3
- 244000134552 Plantago ovata Species 0.000 claims 1
- 235000003421 Plantago ovata Nutrition 0.000 claims 1
- 239000009223 Psyllium Substances 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 229940070687 psyllium Drugs 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract description 81
- 241001465754 Metazoa Species 0.000 abstract description 51
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 41
- 241000282472 Canis lupus familiaris Species 0.000 abstract description 38
- 210000004369 blood Anatomy 0.000 abstract description 23
- 239000008280 blood Substances 0.000 abstract description 23
- 208000017169 kidney disease Diseases 0.000 abstract description 21
- 230000017531 blood circulation Effects 0.000 abstract description 17
- 230000002503 metabolic effect Effects 0.000 abstract description 14
- 230000002550 fecal effect Effects 0.000 abstract description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 7
- 241000282326 Felis catus Species 0.000 abstract description 6
- 230000000112 colonic effect Effects 0.000 abstract description 6
- 230000003139 buffering effect Effects 0.000 abstract description 4
- 230000007413 intestinal health Effects 0.000 abstract description 4
- 150000004666 short chain fatty acids Chemical class 0.000 description 24
- 235000021391 short chain fatty acids Nutrition 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 20
- 210000001072 colon Anatomy 0.000 description 20
- 239000001913 cellulose Substances 0.000 description 17
- 229920002678 cellulose Polymers 0.000 description 17
- 239000000758 substrate Substances 0.000 description 17
- 230000007423 decrease Effects 0.000 description 16
- 238000000855 fermentation Methods 0.000 description 16
- 230000004151 fermentation Effects 0.000 description 16
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 15
- 210000003608 fece Anatomy 0.000 description 14
- 230000000968 intestinal effect Effects 0.000 description 14
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 12
- 241000282465 Canis Species 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 11
- 239000000446 fuel Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 230000003647 oxidation Effects 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 229940109239 creatinine Drugs 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 244000005706 microflora Species 0.000 description 8
- 150000003626 triacylglycerols Chemical class 0.000 description 8
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 7
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 229910002092 carbon dioxide Inorganic materials 0.000 description 7
- 239000001569 carbon dioxide Substances 0.000 description 6
- 210000001842 enterocyte Anatomy 0.000 description 6
- 230000029142 excretion Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 5
- -1 for example Chemical class 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002699 waste material Substances 0.000 description 5
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 4
- 208000001647 Renal Insufficiency Diseases 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 201000006370 kidney failure Diseases 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 208000010444 Acidosis Diseases 0.000 description 3
- 241000252983 Caecum Species 0.000 description 3
- 240000008886 Ceratonia siliqua Species 0.000 description 3
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 3
- 238000012404 In vitro experiment Methods 0.000 description 3
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 3
- 102000043296 Lipoprotein lipases Human genes 0.000 description 3
- 206010027417 Metabolic acidosis Diseases 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 210000004534 cecum Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 201000005991 hyperphosphatemia Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 3
- 229940012843 omega-3 fatty acid Drugs 0.000 description 3
- 239000006014 omega-3 oil Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- FERIUCNNQQJTOY-DOMIDYPGSA-N (114C)butanoic acid Chemical compound CCC[14C](O)=O FERIUCNNQQJTOY-DOMIDYPGSA-N 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229940040387 citrus pectin Drugs 0.000 description 2
- 239000009194 citrus pectin Substances 0.000 description 2
- 235000021245 dietary protein Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 2
- 229960000511 lactulose Drugs 0.000 description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 229920005610 lignin Polymers 0.000 description 2
- 230000003050 macronutrient Effects 0.000 description 2
- 235000021073 macronutrients Nutrition 0.000 description 2
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 2
- 229940033080 omega-6 fatty acid Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 208000001649 Pica Diseases 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 235000005550 amino acid supplement Nutrition 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000004953 colonic tissue Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Abstract
A pet food product containing fermentable fibers which repartitions nitrogen and increases colonic blood flow in companion animals such as cats and dogs to promote intestinal health, and improves clinical signs in animals suffering from renal disease. The fermentable fibers have an organic matter disappearance of 15 to 60 percent when fermented by fecal bacteria for a 24 hour period, the fibers being present in amounts from about 1 to 11 weight percent of supplemental total dietary fiber. The pet food product also improves several important clinical indicators in the renal patient and includes adequate protein, has low phosphorus levels, improves metabolic buffering, and lowers blood triglyceride levels in the animal.
Description
FOOD COMPOSITION FOR PETS
DESCRIPTION OF THE INVENTION
This invention relates to a pet food composition and a product containing fermentable fibers with nitrogen distribution and increases in colon blood flow in companion animals such as dogs and cats to promote intestinal health, and improves clinical signs in animals that suffer from kidney disease. Renal failure is one of the most common causes of death in dogs. In animals suffering from kidney disease, several blood indices are used to determine the severity of the disease. These indices include blood urea nitrogen (BUN) and creatinine. BUN and creatinine levels in the bloodstream increase during the development of kidney failure due to damage to the kidney of the animals which makes the kidney unsuitable for filtering waste products. Because inadequate filtration of waste products is the fundamental basis of kidney disease, BUN and creatinine are considered to be the main indicators of kidney disease. Many dogs suffer from poor health due to insufficient renal function. It is desirable to reduce the tension that is stable in the kidneys of dogs with this condition or disease. A factor that contributes to such tension are metabolites that contain nitrogen in the blood. The nitrogen in the blood is removed mainly by the kidneys. Weakened kidneys can overwork by trying to remove nitrogen from the blood, resulting in kidney failure. Therefore, there is a need for a method to reduce the amount of nitrogen in the blood of dogs without using the kidneys. In extreme cases, medical devices such as dialysis machines can be used to remove nitrogen in the blood. However, in the case of dogs, this solution is usually prohibitive in terms of costs. In addition, in lesser cases of less severe renal insufficiency, therefore, less invasive techniques are desirable. Particularly low-cost techniques that are easy to administer are desirable. Some research has been conducted in the area of nitrogen distribution. This involves using bodily methods of removing waste other than the kidneys to remove nitrogen from the blood. Younes et al., FASEB J. 8: A186 (1994) (Excerpt) have experimented using a diet containing fermentable fiber to increase urea elimination in the rat caecum. However, these experiments have been limited to the rat, which has a different metabolism compared to the dog. For example, the dog has an unstacked intestine, as opposed to the intestine sacculated in the rat. The dog has a non-functional caecum compared to the functional caecum in the rat; and the dog does not practice coprophagia, as the rat does. Other clinical parameters which are important for animals suffering from kidney disease are the levels of phosphorus, carbon dioxide and triglycerides. Hyperphosphatemia (abnormally high phosphorus levels in the blood) often manifests itself during kidney disease. Previous scientific research has indicated that a decrease in dietary intake of phosphorus is beneficial in slowing the progression of kidney disease. However, prior commercial formulations of pet food have been unable to provide low levels of phosphorus in the diet and still meet all the amino acid requirements of the dogs because the phosphorus component in such diets is derived mainly from elevated ingredients. in proteins. Therefore, a decrease in the phosphorus content of the diet requires a decrease of the protein components in the diet at concentrations which are insufficient to supply the amino acid requirements of the animal. Carbon dioxide concentrations are an indicator of the metabolic damping concentration (acid-base balance) that occurs in an animal. Metabolic acidosis becomes a problem for an animal suffering from kidney disease, and high concentrations of carbon dioxide are indicators of a lack of buffering. Another parameter which is important in animals suffering from kidney disease is the concentration of triglycerides in blood. It is important in the animal suffering from kidney disease that the concentration of triglycerides is often higher compared to normal animals. It would be desirable to be able to control these additional parameters in a renal patient through diet. Current diet therapies to reduce measured concentrations of BUN, creatinine and phosphorus include decrease in the amount of protein in the diet at concentrations where amino acids are present in insufficient amounts. A decrease in the concentration of dietary protein decreases the BUN since the urea is finally derived from the protein. However, such diets can result in other problems developing for the animal as the protein needs of the animals are not met. Accordingly, the need for a food composition for pet food which results in a decrease in the concentrations of BUN, creatinine and phosphorus in the animal without decrease of the food protein to insufficient levels remains in the art. The need also remains for a low-cost, easy-to-administer method to reduce the amount of nitrogen in the blood of companion animals such as dogs and cats, without using the kidneys and increasing the blood flow of the animal's colon to improve and promote intestinal health There also remains a need in this technique for a food composition for pet food which provides improved metabolic buffering and which lowers the triglyceride concentrations in the renal patient. The present invention meets these needs by providing a pet food composition which improves several important clinical indicators in the renal patient and which includes adequate protein, which has low phosphorus concentrations, which improves metabolic damping and lowers triglyceride levels in blood in the animal. The pet food composition of the present invention also distributes nitrogen in the animal by increasing the excretion of nitrogen via the colon. The pet food composition of the present invention also increases colon blood flow, increases the amount of nitrogen excreted. Feeding an animal with a diet comprising the composition results in health benefits by reducing the strain of the animal's kidneys and improving the clinical indicators while providing improved metabolic damping and decreasing blood triglyceride concentrations. In addition, an increased blood flow from the colon promotes a healthy bowel and keeps the colon tissues irrigated. According to one aspect of the present invention, there is provided a pet food composition containing a mixture of at least two fermentable fibers which have a disappearance of organic matter of 15 to 60 percent when fermented by faecal bacteria during a period of 24 hours, the fibers are present in amounts from about 1 to 11 weight percent of the total supplemental food fiber. The pet is kept under the diet for a sufficient period of time to allow the fermentable fibers to ferment in the colon of the animal. The fermentation results in an increased amount of bacteria in the colon of the animal, which results in the nitrogen being excreted through the animal's feces. The fermentation also provides an improved availability of metabolic fuel, in the form of short chain fatty acids such as, for example, butyrates which are used by the intestinal cells of the dog. Finally, animals fed a diet containing the fermentable fibers increased colonic blood flow, with an increased blood flow in such a way as to provide additional metabolic fuel such as, for example, glucose, to intestinal cells. In addition, by keeping the animal in the diet, the pet food composition of the present invention also acts to reduce the concentrations of BUN and creatinine in the animal. Typically, the composition comprises from about 10 to about 32% crude protein, from about 8 to about 20% fat, from about 3 to about 25% total food fiber, and fermentable fibers. Preferably, the pet food composition contains 2 to 9 weight percent supplemental total dietary fiber of fermentable fibers. More preferably, the pet food composition contains from 3 to 7 weight percent of supplemental total dietary fiber of fermentable fibers. Much more preferably, the pet food composition contains from 4 to 7 weight percent of total supplemental food fiber of fermentable fibers. Preferably, the fermentable fibers have a disappearance of organic matter of 20 to 50 percent. More preferably, the fermentable fibers have a disappearance of organic matter of 30 to 40 percent. The fermentable fibers are preferably selected from the group consisting of beet pulp, gum arabic, talha gum (a form of gum arabic), psilium, rice bran, locust bean gum, citrus pulp, pectin, fructooligosaccharides, mannanoligosaccharides and mixtures of the same. More preferably, the fermentable fibers are selected from the group consisting of beet pulp, gum arabic and fructo-oligosaccharides. More preferably, the fermentable fibers are a mixture of beet pulp, talha gum and fructooligosaccharides. A preferred weight ratio of beet pulp to fructooligosaccharides in the fermentable fiber mixture is from about 3: 1 to 6: 1, and more preferably 4: 1. A preferred weight ratio of beet pulp to rubber talha with respect to fructooligosaccharides is 6: 2: 1.5. The beet pulp provides a source of butyrate to the intestinal cells of the animal. Optionally, the composition may also comprise a phosphorus content less than about 0.25% by weight to avoid hyperphosphatemia. The composition may also optionally contain potassium citrate as a metabolic buffering agent. It has been found that the inclusion of potassium citrate decreases metabolic acidosis in animals with kidney disease. The low phosphorus mode of the pet food composition comprises from about 10 to about 32% crude protein, from about 2 to about 20% fat and from about 3 to about 25% total food fiber, wherein the percentage of phosphorus is less than about 0.25%, all percentages are by weight. In order to maintain this low phosphorus content and at the same time provide an adequate amount of amino acids, a combination of protein sources containing low phosphorus content is used. Preferred sources of protein with a low phosphorus content for the composition include soy protein isolate and corn gluten meal. Optionally, the composition further includes L-lysine and L-tryptophan as amino acid supplements. The preferred percentages (by weight) of the protein and the amino acid components of the composition are: from about 5 to about 15% of soy protein isolate, from about 0.5 to about 2.5% of corn gluten meal, from about 0.01 to about 0.22% L-lysine, and from about 0.01 to about 0.22% L-tryptophan. A preferred weight ratio of soy protein isolate to corn gluten meal relative to L-tryptophan relative to L-lysine is 420: 46.5: 5: 1. Accordingly, a feature of the present invention is to provide a pet food product which distributes nitrogen in animal pets by increasing nitrogen excretion via the colon which provides a low cost and easy to administer method to reduce the amount of nitrogen in the blood of animals without using the kidneys. A further feature of the present invention is to provide a pet food product which increases the blood flow of the colon in animals to promote intestinal health. A further objective of the present invention is to provide a pet food composition which improves the clinical indicators in the renal patient, improves metabolic damping and lowers the concentrations of three blood glycerides in the animal. These and other features and advantages of the present invention will become apparent from the following detailed description, the accompanying drawings and the appended claims. By way of example, reference is now made to the drawings, in which: Figure 1 shows the oxidation of butyrate [1-14C] by canine intestinal cells; and Figure 2 shows the oxidation of glucose [U-14C] by canine intestinal cells. The present invention utilizes a pet food composition containing fermentable fibers to remove nitrogen from the blood of animal pets, to improve blood flow to colon tissues and to improve the availability of metabolic fuel for intestinal cells. The composition also, when administered as a feed to a companion animal such as a dog or a cat, results in an improvement in various clinical signs associated with kidney disease. This is done by adding fibers that have some fermentation capacity in the diet of the animals. These fibers are a preferred nutritional source for bacteria in the colon, which provides an increase in the amount of bacteria in the colon. These bacteria also require nitrogen to reproduce. This nitrogen is derived from urea that is extracted from the intestinal lumen of the portal blood. Once it is inside the intestinal lumen, the urea nitrogen and the main carbon structures of the fibers are synthesized in bacterial protein and subsequently excreted in the feces. The composition of the present invention also acts to increase the blood flow of the colon. An improved blood flow of the colon promotes a healthy bowel by keeping the tissues of the colon irrigated with nutrients. Although not wishing to be bound by any particular theory, the mechanism by which this increase in blood flow occurs is considered to be either: 1) the short chain fatty acids cause relaxation of the colonic artery arteries; or 2) the absorption of short chain fatty acids increases the intestinal metabolic activity, which induces an increased blood flow. The availability of metabolic fuel for intestinal cells is improved. That is, the fermentation of the fibers in the small and large intestine of the animal produces short chain fatty acids such as, for example, butyrates, which are used by the enterocytes (cells of the small intestine) and colonocytes (cells in the intestine). thick). Therefore, the present invention provides both a direct fuel source for exogenous cell tissues in the small intestine and in the colon, as well as an indirect source of fuel (via increased colonic blood flow) to endogenous cell tissues. The incorporation of fermentable fiber in the diet can also have several other beneficial effects. These include reduction of colonic histopathologies, increased colonic tissue weight or proliferation of epithelial cells, and beneficial alteration of the intestinal microbiota. Short chain fatty acids (SCFA) produced by carbohydrate fermentation are associated with trophic effects in the colon tissue and inhibition of the potentially pathogenic intestinal microbiota. The present invention uses the pet food composition containing fermentable fibers which show certain percentages of disappearance of organic matter. The fermentable fibers used in the present invention have a disappearance of organic matter (OMD) from about 15 to 60 percent when fermented by fecal bacteria in vitro, over a period of 24 hours. That is, from about 15 to 60 percent of the total organic matter originally present is fermented and converted by fecal bacteria. The disappearance of organic matter from the fibers is preferably 20 to 50 percent, and more preferably 30 to 40 percent. Therefore, the percentage of OMD in vitro can be calculated as follows:. { l- [(OM residue - OM blank) / initial OM]} x 100, where the OM residue is the organic matter recovered after 24 hours of fermentation, the white OM is the organic matter recovered in the corresponding white tubes (ie, tubes containing medium and faeces diluted, but without substrate) and initial OM is the organic matter placed in the tube before fermentation. Additional details of the procedure are found in Sunvold et al, J.Anim. Sci. 1995, vol.73: 1099-1109. The fermentable fibers which are useful in the present invention produce short chain fatty acids (SCFA) within a range of from about 28 to about 85 mmoles of SCFA per 1000 calories (kcal) of etabolizable energy (ME), and more preferable within a range of from about 42 to about 71 mmoles of SCFA per 1000 Kcal of ME. This is the same as a composition which has a total fermentable fiber content which provides from about 100 to about 350 mmoles of SCFA / kg of diet.
The millimoles of SCFA per 1000 kilocalories of metabolizable energy are calculated by first calculating the total calories of metabolizable energy (ME) in a given diet composition per kilogram of the composition. The amount of grams per 1000 kcal of ME can be derived from the first calculation. The grams and then the millimoles of the fermentable fiber components of the composition can then be calculated. The fermentable fiber of the present invention can be any source of fiber to produce significant amounts of SCFA. The term "significant amounts" of SCFA, for purposes of this invention, are amounts greater than 0.5 mmoles of total SCFA / gram of substrate in a 24-hour period. Preferred fibers include beet pulp, gum arabic (which includes talha gum), psilium, rice bran, locust bean gum, citrus pulp, pectin, fructooligosaccharides, mannaoligosaccharides and mixtures of these fibers. More preferably, the fermentable fibers are selected from the group consisting of beet pulp, gum arabic, and fructo-oligosaccharides. More preferably, the fermentable fibers are a mixture of beet pulp, talha gum and fructooligosaccharides. A preferred weight ratio of beet pulp to fructooligosaccharides in the fermentable fiber mixture is from about 3: 1 to 6: 1, and most preferably 4: 1. A preferred weight ratio of beet pulp to rubber talha to fructooligosaccharide is 6: 2: 1.5. Fermentable fibers are used in the pet food composition in amounts of 1 to 11 weight percent supplemental total food fiber, preferably 2 to 9 weight percent, and most preferably 3 to 7 weight percent. weight, and much more preferably from 4 to 7 weight percent. A definition of "supplemental total dietary fiber" first requires an explanation of the "total dietary fiber". The term "total food fiber" is defined as the residue of plant foods which are resistant to hydrolysis by digestive enzymes of the animal. The main components of the total food fiber are cellulose, hemicellulose, pectin, lignin and gums (as opposed to "crude fiber", which only contains some forms of cellulose and lignin). The term "supplementary total food fiber" is that food fiber which is added to the food product above and surpassing any food fiber naturally present in other food product components. In addition, it is considered a "fiber source" for example when it consists predominantly of fiber. Other clinical indicators which are important for the renal patient are the concentrations of phosphorus, carbon dioxide and triglycerides in the blood. Abnormally high phosphorus concentrations often manifest themselves during kidney disease. One embodiment of the present invention provides a pet food composition with a low phosphorus content containing from about 10 to about 32% crude protein, from about 8 to about 20% fat, and from about 3 to about 25%. % of total food fiber, where the percentage of phosphorus is less than about 0.25%, all percentages by weight. Low phosphorus levels decrease the progression of kidney disease and control hyperphosphatemia through diet. In order to maintain this low phosphorus content and at the same time provide an adequate amount of amino acids in the diet, a combination of protein sources containing little phosphorus is used. Preferred low sources of protein phosphorus for the composition include soy protein isolate and corn gluten meal. Moderate amounts of these high-quality protein sources help maintain the glomerular filtration rate, lean muscle mass and other bodily functions. Optionally, the composition further includes L-lysine and L-tryptophan, amino acids which are necessary for the good health of an animal. The preferred percentages (by weight) of the protein and the amino acid components of the composition are: from about 5 to about 15% of soy protein isolate, from about 0.5 to about 2.5% of corn gluten meal, from about 0.01 to about 0.22% L-lysine and from about 0.01 to about 0.22% L-tryptophan. A preferred weight ratio of soy protein isolate to corn gluten meal relative to L-tryptophan relative to L-lysine is 420: 46.5: 5: 1. The concentrations of carbon dioxide in the blood gases in the animal are also indicators of alterations in the acid-base balance of the animal. Metabolic acidosis, a condition in which too much acid is present in the blood, often manifests itself in an animal with kidney disease. Such a condition can be controlled by adding potassium citrate in the animal's diet to improve metabolic buffering. The composition of the present invention also acts to lower triglycerides in blood serum in an animal with kidney disease. The decrease in the concentration of triglycerides in blood in an animal with kidney disease is important since high triglyceride levels often manifest with the disease. By altering the concentrations of fats and fatty acids in the animal's diet, triglycerides can be reduced. The animal is fed a diet comprising from about 10 to about 32% crude protein, from about 8 to about 20% fat, all percentages by weight. The diet also includes fermentable fibers which have a disappearance of organic matter of 15 to 60 percent when fermented by faecal bacteria over a period of 24 hours, the fibers are present in amounts from about 1 to 11 weight percent fiber supplementary total food. Because fermentable fibers act to decrease BUN and the distribution of nitrogenous residues from the urine to the animal's faeces, excessive concentrations of dietary fat are not required to dilute the calories provided by the proteins in the diet. Therefore, the ratio of calories from the protein in the diet to the calories from the fat in the diet preferably is greater than about 0.40: 1. Such a diet provides a much higher ratio of protein calories to fat compared to previous diets while decreasing triglyceride concentrations. The diet may also include sources of omega-6 and omega-3 fatty acids in a ratio of about 1: 1 to about 10: 1 of omega-6 fatty acids with respect to omega-3 fatty acids. Such a combination of these fatty acids increases the activity of lipoprotein lipase (LPL) in the animal. The increased activity of LPL increases the oxidation of fatty acids and therefore decreases the concentrations of triglycerides in blood. The proportion of omega-6: omega-3 fatty acids also results in decreased intrarenal blood pressure and reduces inflammatory mediators. In order that the invention is more easily understood, reference is made to the following examples which are designed to illustrate the invention, but do not limit the scope thereof.
Example 1
An experiment is carried out to determine the effect of the fermentation capacity of dietary fiber on bacterial expression in feces, and the division of waste nitrogen between urine and faeces. Twenty dogs mestizos (Beagles) female, fed on purpose, were fed nutritionally complete diets containing one of four fiber substrates: cellulose (low fermentation capacity), beet pulp (moderate fermentation capacity, moderate fermentation speed), fructooligosaccharides (FOS, moderately high fermentation capacity, rapid fermentation rate) and a mixture of talha gum, beet pulp and FOS (see table 1). The nitrogen content of the diet, lyophilized urine and feces were determined and the nitrogen balance was calculated (see tables 2 to 5). The excretion of bacterial nitrogen was determined by analyzing the lyophilized feces to determine the purine concentration. Feeding with fermentable fiber to dogs decreases the urinary excretion of nitrogen and increases fecal nitrogen excretion. The increased fecal nitrogen occurs due to an increase in the excretion of microbial nitrogen in the faeces that results from a consumption of fermentable fiber. This experiment shows that the inclusion in the diet of fermentable fiber can divide the waste nitrogen from the urine to the faeces.
Table 1 Composition of ingredients of the basal diet
Cellulose diet: Solka Floc 6.0% Beet pulp diet: Beet pulp 6.0% FOS diet: FOS 1.5% Mix diet: Beet pulp 6.0%, Talha 2.0% gum, FOS .5%
Table 2 Ingestion of dry matter and digestion capacity of diets that differ in the fiber source
The ingestion is numerically smaller and the capacity of digestion is greater for the FOS diet.
Table 3 Nitrogen excretion and digestion capacity of diets that differ in fiber source
* g d = grams per day a The intake of nitrogen tends to reflect the numerical differences observed in the ingestion of dry matter. The fecal nitrogen output is higher for the beet pulp and mixture diets, intermediate for cellulose and lower for the FOS diet. The output of urinary nitrogen is numerically lower for dogs fed diets of beet pulp, mix and FOS. The nitrogen balance is higher for beet pulp and FOS diets, compared to cellulose and mixer diets. The nitrogen digestion capacity is higher for the cellulose diet, intermediate for FOS diets of beet pulp, and lower for the mixing diet. Faecal nitrogen expressed as a percentage of excreted nitrogen is higher for the mix diet, FOS diet and beet pulp diets, compared to the cellulose diet. The output of urinary nitrogen as a percentage of nitrogen intake is numerically greater with the cellulose diet.
Table 4
Microbial nitrogen and bicinchoninic acid (BCA) true protein in feces of dogs fed diets that differ in fiber source
The output of microbial nitrogen is higher for the mix and pulp beet diets, and lower for the FOS and cellulose diets. The output of the true protein of bicinchoninic acid (BCA) is greater for the mixture, intermediate for beet pulp and cellulose diets, and lower for the FOS diet. The true BCA protein as a percentage of fecal DM is higher for beet pulp and mix diets, compared to cellulose and FOS diets.
Table 5
Blood flow (ml / min / 100 g of colon) through the dog's colic artery
The average blood flow of the colon is greater with the FOS and mix diets, intermediate with the diet of beet pulp and lower with the cellulose diet.
Example 2
An in vitro experiment is carried out to determine the fermentation capacity of fibrous substrates by dog fecal microflora. The feces of three female Pointers English dogs were used as the source of anaerobic microflora inoculum. The substrates were fermented for 24 hours and then the concentrations of various short chain fatty acids were determined. Table 6 shows the results. The data show that Solka Floc (a cellulose source) is essentially non-fermentable, with an insignificant amount of SCFA produced while lactulose is the most fermentable fiber. Fibers within the scope of the present invention, such as karaya gum, xanthan gum, gum arabic, beet pulp, talha gum and locust bean produce moderate amounts of SCFA, intermediate those produced by Solka Floc and lactulose. In addition, the beet pulp produces the highest amount of butyrate, which is an important energy substrate for the colonocytes.
Table 6 Short-chain fatty acids produced by dog faecal bacteria on various fiber substrates in a 24-hour period
Example 3
In vitro experiments are carried out to determine the percentage of disappearance of organic matter (OMD) from fibrous substrates when exposed to faecal microflora of dog and cat. Three female English Pointer dogs provide fecal samples for the anaerobic microflora of dogs. The data feces of short hair, one female and two males, were used as the inoculum source of the anaerobic cat microflora. The amount of organic matter was determined for the various substrates. Subsequently, these substrates were fermented for 24 hours and the amount of remaining organic matter was determined. Table 7 presents the results, provided as the percentage of OMD. The data show that Solka Floc (a cellulose source) has the smallest percentage of OMD while the citrus pectin has the highest percentage. Fibers within the scope of the present invention, such as beet pulp, citrus pulp, carob and talha gum have intermediate OMD percentages.
Table 7
Disappearance of organic matter (%) from various substrates after being subjected to dog and cat microflora for 24 hours
Example 4
An in vitro experiment is carried out to determine the fermentation capacity of the fiber sources selected by dog fecal microflora. The inoculations come from dogs adapted to a diet containing non-fermentable fiber (Solka Floc, a source of cellulose) or a diet containing fermentable fiber (citrus pulp) within the scope of the invention.
The faeces of three English Pointer dogs adapted to each diet were used as a source of microflora to evaluate the production of short-chain fatty acid (SCFA) from substrates of carob, citrus pulp and citrus pectin. The substrates were fermented for 6 and 12 hours. In tables 8 and
9 the results are shown. The data indicate that the production of acetate and total SCFA is significantly higher after
6 and 12 hours of fermentation from dogs that consume a diet containing citrus pulp, and may indicate that cellulose (Solka Floc) causes a decrease in microbial activity.
Table 8
Production of acetate (mmol / gram of organic matter) of Solka Floc fibers and citrus pulp of various substrates
Table 9
Total production of SCFA (mmol / gram of organic matter) of Solka Floc and citrus pulp fibers on various substrates
Example 5
Enterocytes and colonocytes were isolated from the intestines of adult dogs and grown in vitro using modified procedures of Kight and Fleming, J. Nutr. Biochem. 6:27 (1995) and Marsman and McBurney, J. Nutr. 125: 273 (1995). The use of metabolic fuel by the cells was determined by measuring the production of 14C02 from radiolabeled substrates. Oxidation rates or rates (nmoles of substrate per hour per mg of cell dry matter) for [1-14C] -butyrate (5 mM), [U-14C] -glucose (5 mM) and L- [U14C] -glutamine (2.5 mM) were 13.5 + 3.5, 6.5 + 0.96, and 8.1 + 0.21 for canine colonocytes and 18.7 + 1.7, 16.1 + 1.0 and 32.0 + 4.3 for canine enterocytes. Figure 1 shows the oxidation of [1-14C] -butyrate by canine intestinal cells. Oxidation of butyrate by colonocytes (cells in the large intestine) and enterocytes (cells in the small intestine) is not affected by supplementation of the medium with glucose (5 mM), glutamine (2.5 mM), or β-hydroxybutyric acid (BHBA) ) (5 mM). Figure 2 shows the oxidation of] U-14C] glucose by canine ntestinal cells. The oxidation of glucose (5 mM) by colonocytes is not diminished by the addition of 2.5 mM glutamine or 5 mM β-hydroxybutyrate to the medium. In contrast, the addition of butyrate decreases glucose oxidation by canine enterocytes. From these results, canine enterocytes use butyrate with higher affinity than glutamine or glucose, while canine colonocytes seem to use glucose and butyrate with equal affinity. The implications of these observed results indicate that feeding the dog with a diet containing a source of fermentable fibers which are broken down into short chain fatty acids provides a source of metabolizable fuel for canine intestinal cells. Additionally, since canine intestinal cells use glucose as a fuel source, the additional benefit of increased colonic blood flow resulting from a diet containing fermentable fibers improves the availability of this important source of fuel for intestinal cells.
Example 6
An experiment is carried out to determine the effects on certain clinical signs in dogs with kidney disease. Table 10 below summarizes the percentage of calories derived from each macronutrient in a conventional pet food diet, compared to the diet of the present invention. Table 11 summarizes the results obtained from four adult dogs suffering from kidney disease and compares their clinical BUN, creatinine, phosphorus, carbon dioxide and triglyceride levels before and after consumption of the diet of the present invention.
TABLE 10
Percentages of calories of each macronutrient in conventional diets compared to the diet of the present invention for dogs with kidney disease Diet Fatty Protein Carbohydrate conventional 10.6 38.7 50.8 Formulation of the present invention 12-9-17.3 29.4-31.1 57.7-51.6
As can be seen, the diet of the present invention provides a much higher percentage of calories from protein and less from fats, compared to previous diets.
TABLE 11
Summary of the results of four dogs before and after consumption of the diet of the present invention:
BUN Creatinine Phosphorus C02 Triglycerides before3 60.3 3.4 5.9 19.0 240.0 After 51.8 2.8 5.3 21.8-99.8
Normal Interval 6.32 0.4-1.1 2.7-5.8 14-30 31-105
Before the consumption of the diet of the present invention, the dogs were fed a standard commercial diet used with kidney patients.
Although certain representative embodiments and details have been shown for purposes of illustrating the invention, it will be apparent to those familiar with the art that various changes can be made to the methods and apparatuses described herein without departing from the scope of the invention, which it is defined in the attached clauses.
Claims (18)
1. Pet food product, which comprises a composition containing fermentable fibers, the fermentable fibers comprise a mixture of beet pulp, talha gum and fructooligosaccharides, a mixture of beet pulp, gum arabic and fructooligosaccharides, fermentable fibers which have a disappearance of organic matter from 15 to 60 percent when fermented by faecal bacteria over a 24-hour period, the fibers are present in amounts from about 1 to 11 weight percent of total supplemental dietary fiber.
2. Pet food product, as described in clause 1, wherein the pet food composition contains from 2 to 9 weight percent of total supplementary dietary fiber of fermentable fibers.
3. Pet food product, as described in clause 1, wherein the pet food composition contains from 3 to 7 weight percent of total supplemental dietary fiber of fermentable fibers.
4. Pet food product, as described in clause 1, wherein the pet food composition contains from 4 to 7 weight percent of total supplementary dietary fiber of fermentable fibers.
5. Food product for pets, as described in clause 1, where the fermentable fibers have a disappearance of organic matter from 20 to 50 percent.
6. Food product for pets, as described in clause 1, where the fermentable fibers have a disappearance of organic matter from 30 to 40 percent.
7. Pet food product, as described in clause 1, wherein the weight ratio of beet pulp to fructo-oligosaccharides is from about 3: 1 to 6: 1.
8. Pet food product, as described in clause 1, where the weight ratio of beet pulp to gum to fructooligosaccharides is 6: 2: 1.5.
9. Pet food product, as described in clause 1, wherein the composition has less than about 0.25% phosphorus, all percentages are by weight.
10. Pet food product, as described in clause 1, wherein the composition further comprises fermentable fibers which are selected from the group consisting of psyllium, rice bran, locust bean gum, citrus pulp, pectin, manno-oligosaccharides and mixtures thereof. same.
11. Pet food product, as described in clause 1, in which the total fermentable fiber content of the composition produces from about 100 to about 350 mmoles of SCFA / kg of diet.
12. Pet food product, as described in clause 1, wherein the composition comprises from about 10 to about 32% crude protein, from about 8 to about 20% fat and from about 3 to about 25% dietary fiber total.
13. Pet food product, as described in clause 12, in which raw protein is supplied from soy protein isolate and corn gluten meal.
14. Pet food product, as described in clause 12, wherein the composition also includes L-lysine and L-tryptophan.
15. Pet food product, as described in clause 12, in which the composition includes from about 5 to about 15% soy protein isolate, from about 0.5 to about 2.5% corn gluten meal, from about 0.01 to about 0.22% L-lysine and from about 0.01 to about 0.22% L-tryptophan.
16. Pet food product, as described in clause 12, in which the weight ratio of soy protein isolate to corn gluten meal relative to L-tryptophan to L-lysine is 420: 46.5: 5: 1.
17. Pet food product, as described in clause 12, which also includes potassium citrate.
18. Pet food product, as described in clause 12, in which the ratio of protein calories to fat calories in the composition is greater than about 0.40: 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08827405 | 1997-03-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA99007999A true MXPA99007999A (en) | 2000-12-06 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU725604B2 (en) | Pet food composition | |
| US6039952A (en) | Composition and method for improving clinical signs in animals with renal disease | |
| JP2860264B2 (en) | Feed for pet animals containing fermentable fiber and method for treating gastrointestinal disorders | |
| Jha et al. | Dietary fiber and protein fermentation in the intestine of swine and their interactive effects on gut health and on the environment: A review | |
| Taylor et al. | Some nutritional aspects of ageing in dogs and cats | |
| RU2197835C2 (en) | Food composition for domestic animals for regulation of response to glycemia after meal in said animals | |
| Laplace et al. | Associative effects between two fibre sources on ileal and overall digestibilities of amino acids, energy and cell-wall components in growing pigs | |
| CA2439635C (en) | Use of carbohydrate source to limit weight gain in cats | |
| WARD et al. | The effect of saturation, chain length of pure triglycerides, and age of bird on the utilization of rye diets | |
| Mikkelsen et al. | Effect of fermented liquid feed (FLF) on growth performance and microbial activity in the gastrointestinal tract of weaned piglets | |
| Harris | Feeding management of elite endurance horses | |
| Choct | Soluble non-starch polysaccharides affect net utilisation of energy by chickens. | |
| Venter et al. | Possible metabolic consequences of fermentation in the colon for humans | |
| Hill et al. | Effects of changing the fatty acid composition of calf starters | |
| Marounek et al. | Fermentation of carbohydrates and yield of microbial protein in mixed cultures of rabbitcaecal microorganisms | |
| MXPA99007999A (en) | Pet food composition | |
| CN118633735A (en) | Application of the composition in preparing a product for improving constipation | |
| US20040022828A1 (en) | Use of carbohydrate source to limit weight gain in cats | |
| HK1026123A (en) | Pet food composition | |
| Eckstein | Fat in Nutrition | |
| Frape | Recent research into the nutrition of the horse | |
| Booth | Effect of forage addition to the diet on rumen development in calves | |
| De Goe | Equine dietary supplements: driving factors and discipline differences | |
| CN117562173A (en) | Yeast protein-dietary fiber compound and preparation method and application thereof | |
| Verbrugghe | Nutrition and gastro-intestinal disease: there is no single GI diet. |